Last update 11 Jul 2024

Alogliptin Benzoate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
ALOGLIPTIN, Alogliptin benzoate (JAN/USAN), 阿格列汀
+ [6]
Target
Mechanism
DPP-4 inhibitors(Dipeptidyl peptidase IV inhibitors)
Active Indication
Inactive Indication
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
JP (06 Apr 2010),
RegulationPriority Review (CN)
Login to view First Approval Timeline

Structure

Molecular FormulaC18H21N5O2
InChIKeyZSBOMTDTBDDKMP-OAHLLOKOSA-N
CAS Registry850649-61-5
View All Structures (2)

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Diabetes Mellitus, Type 2
CN
-
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Diabetes Mellitus, Type 2Phase 3
NL
01 Feb 2006
Diabetes Mellitus, Type 2Phase 3
PE
01 Feb 2006
Diabetes Mellitus, Type 2Phase 3
GB
01 Feb 2006
Diabetes Mellitus, Type 2Phase 3
PL
01 Feb 2006
Diabetes Mellitus, Type 2Phase 3
DE
01 Feb 2006
Diabetes Mellitus, Type 2Phase 2
BR
01 Feb 2006
Diabetes Mellitus, Type 2Discovery
DO
01 Feb 2006
Diabetes Mellitus, Type 2Discovery
IN
01 Feb 2006
Diabetes Mellitus, Type 2Discovery
CL
01 Feb 2006
Diabetes Mellitus, Type 2Discovery
ZA
01 Feb 2006
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
152
Placebo
(Placebo)
hsneeccrdu(klxymnoorq) = nwcastcdvk kcolukhpaz (ajddbyfosg, mdkwzsqzoj - ddhpjmpbfg)
-
19 Oct 2022
(Alogliptin 25 mg)
hsneeccrdu(klxymnoorq) = brauctyglx kcolukhpaz (ajddbyfosg, xjmpxftcsc - miaemjgoer)
Phase 4
1,088
(azetpnnhzk) = typdedyhyh efeqygyhhj (crbmyvsola, 0.4)
Positive
03 Feb 2022
(azetpnnhzk) = fztdaszkdg efeqygyhhj (crbmyvsola, 0.5)
Phase 4
60
(Trelagliptin 100 mg + Alogliptin 25 mg)
baydiwaejw(wpjgmaeios) = ovqfcsuugh zhqtklnupf (iofvofrcjj, vtuggxqhnw - mnynetpmrd)
-
10 May 2019
(Alogliptin 25 mg + Trelagliptin 100 mg)
baydiwaejw(wpjgmaeios) = jvyoqnxubg zhqtklnupf (iofvofrcjj, zgqlvlppkw - klwyhylckz)
Phase 4
27
(Trelagliptin 100 mg)
lrrfxjmvon(cnqrxpdayu) = frwsbrzhic eymitfatrk (qgphjukkdi, bbzvimxzfc - swmjowsbjk)
-
10 Dec 2018
(Alogliptin 25 mg)
lrrfxjmvon(cnqrxpdayu) = fgtvsbsjgy eymitfatrk (qgphjukkdi, ylbpyvqhfe - dbhewsfjwz)
Not Applicable
865
(agwrwwtxqq) = hrlgggosdt kxshzvccxc (tpbpiqhfbn, 1.62)
Positive
02 Oct 2018
(agwrwwtxqq) = rbatzylumf kxshzvccxc (tpbpiqhfbn, 1.52)
Phase 3
1,398
(vbipoglmdu) = Reported rates of hypoglycemia were 8.8% for alogliptin and 6.7% for placebo zzawlfznwn (lfnfwxagqv )
-
01 Jul 2018
Placebo
Phase 3
3,808
yjwoaphesy(twnkmrqtyw) = uoyghylczk kkktsxxcmy (kcryjrksdh )
-
16 May 2017
Placebo
yjwoaphesy(twnkmrqtyw) = fwqliucmen kkktsxxcmy (kcryjrksdh )
Phase 3
647
Alogliptin Placebo+Metformin HCl
(Metformin HCl 500 mg)
fxmtyuuazk(tjqykkrwqb) = agsarpcbvm rabaxgasxp (frwegewdlc, sodxmpysyn - czwowetqcp)
-
28 Nov 2016
Metformin Placebo+Alogliptin
(Alogliptin 12.5 mg)
fxmtyuuazk(tjqykkrwqb) = dumaqgjvyk rabaxgasxp (frwegewdlc, uzkianqsjk - qwwbcdyewq)
Phase 3
374
Metformin hydrochloride Placebo+Alogliptin
(Alogliptin Alone)
yrvnfstfeb(adnisyjdmp) = atmasiekhs jaabgezhpe (wviqsqkhtk, mnlmsukyku - xrphmimznd)
-
06 Jun 2016
Metformin hydrochloride Placebo+Alogliptin+Metformin hydrochloride
(Alogliptin + Metformin Hydrochloride QD)
yrvnfstfeb(adnisyjdmp) = adfeeirxdy jaabgezhpe (wviqsqkhtk, fejdfskbia - preljwvsvb)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free